2 dark yellow tab each containing estradiol valerate 3 mg, 5 medium red tab each containing estradiol valerate 2 mg, dienogest 2 mg, 17 light yellow tab each containing estradiol valerate 2 mg, dienogest 3 mg, 2 dark red tab each containing estradiol valerate 1 mg, 2 white inactive tab
Indications/Uses
Prevention of pregnancy. Treatment of heavy menstrual bleeding (not caused by any disease of the womb) in women who wish to use oral contraception.
1 tab at the same time daily. Woman who has not used a hormonal contraceptive during the previous mth Start Qlaira on the 1st day of the period. Changing from another combined hormonal contraceptive pill Start the day after taking the last active tab of the previous pill. Changing from combined contraceptive vag ring or patch Start on the day of the removal of the ring or patch. Changing from a progestogen-only-method Switch at any day but use extra protective measures during the 1st 9 days of Qlaira use. After having a baby Start between 21 & 28 days after having a baby. If later than 28 days, use a barrier method during the 1st 9 days of Qlaira use.
View Qlaira overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. DVT, pulmonary embolism, blood clot in other organs; disorder affecting blood clotting eg, protein C deficiency, protein S deficiency, antithrombin-III deficiency, Factor V Leiden or antiphospholipid Ab; surgery or immobilization for a long time; heart attack or stroke; angina pectoris, transient ischaemic attack; factors increasing risk of clot in the arteries eg, severe DM w/ blood vessel damage, very high BP, very high level of fat in the blood, hyperhomocysteinaemia; migraine w/ aura; liver disease & liver function not returning to normal; tumour of the liver; cancer or suspected cancer of the breast or genital organs; unexplained vag bleeding.
Family history of breast cancer; liver or gallbladder disease; jaundice; diabetes; depression; Crohn's disease or ulcerative colitis; SLE; hemolytic uremic syndrome; sickle cell disease; hypertriglyceridaemia or +ve family history thereof; surgery/operation or immobilization for a long time; superficial thrombophlebitis; varicose veins; epilepsy; disease that 1st appeared during pregnancy or earlier use of sex hormones (eg, hearing loss, porphyria, gestational herpes, Sydenham's chorea); hereditary angioedema; cardiac or renal insufficiency. Pregnancy patches, chloasma; avoid direct exposure to sunlight or UV light. Risk of developing blood clots; depression or depressive mood. Intolerance to some sugars. Women who just recently gave birth. Do not take if pregnant. Should not be taken while breast-feeding. Not intended for use in females whose periods have not yet started.
Sign Out
